Clinical Trial

Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC

Name: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC — clinical trial record (NCT07355972)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This study is a single arm, open label, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SSc. The study was divided into dose escalation phase and dose expansion phase.

Trial Details

NCT Number	NCT07355972
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions	SSc-Systemic Sclerosis
Enrollment	12 participants
Start Date	2026-01-16
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-21